8. Moore K, Reading C, Deisseroth A, William D, and Belmont J: Stromal support enhances cell-free retroviral vector transduction 
of human bone marrow long term culture initiating cells. Blood 79:1393-1399, 1992. 
9. Wedrychowski A, Henzel W, Huston L, Paslidis N, Ellerson D, McRae M, Seong D, Howard OMZ, and Deisserpth A- 
Identification of proteins binding to interferon-inducible transcriptional enhancers in hematopoietic cells. J Biol Chem 267:4533- 
4540. 1992. 
10. Johnson E, Henzel W, and Deisseroth A: A protein disulfide isomerase isolated from chronic myelogenous leukemia cells alters 
complex formation between nuclear proteins and regulatory regions of interferon-inducible genes. J Biol Chem 267:14412-14417, 
1992. 
11. Sims S, Cha Y, Romine M, Gao P-Q, Gottlieb K, and Deisseroth A: A novel interferon-inducible domain: Structural and 
functional analysis of the human IRF-1 gene promoter. Mol Cell Biol 13:690-702, 1993. 
12. del Giglio A, O’Brien S, Ford R, Saya H, Maiming J, Keating M, Johnston D, Khetan R, El-Naggar A, and Deisseroth A: The 
prognostic value of proliferative cell nuclear antigen expression in chronic lymphoid leukemia. Blood 79:2717-2720, 1992. 
13. Zhang W, Drach J, Andreeff M, and Deisseroth A: Proliferation of hematopoietic cells is accompanied by suppressed expression 
of heat shock protem 70. Biochem Biophvs Res Comm 183:733-738, 1992. 
14. Cha Y, Sims S, Romine M, Kaufmann M, and Deisseroth A: Human interferon regulatory factor-1: Intron/exon organization. 
DNA and Cell Biology 11:605-611, 1992. 
15. Zhang W, Hittelman W, Van N, Andreeff M, and Deisseroth A: The phosphorylation of retinoblastoma gene product in hu man 
myeloid leukemia cells during the cell cycle. Biochem Biophvs Res Comm 184:212-216, 1992. 
16. Zhang W, Hu G, and Deisseroth A: Polymorphism at codon 72 of the p53 gene in human acute myelogenous leukemia. Gene 
117:271-275, 1992. 
17. Hu G, Zhang W, and Deisseroth A: P53 gene mutations in acute myelogenous leukemia. Br J Haematol 81:489-494, 1992. 
18. Kantaijian HM, Talpaz M, Kontoyiaimis D, Guttennjm J, Keating MJ, Estey EH, O’Brien S, Rios MB, Beran M, and Deisseroth 
A: Treatment of chronic myelogenous leukemia in accelerated and blastic phases with daunorubicin, high-dose cytarabine, and 
granulocyte-macrophage colony stimulating factor. J Clin Oncol 10; 398-405, 1992. 
19. ClaxtoD DF, Reading CL, Nagarajan L, Tsujimoto Y, Andersson B, Estey E, Cork MA, Huh YO, Trujillo J and Deisseroth A: 
Correlation of CD2 expression with PML gene breakpoints in patients with acute promyelocytic leukemia. Blood 80:582-586, 
1992. 
20. Korablau S, Xu H-J, del Giglio A, Hu S-X, Zhang W, Smallwood L, Beran M, Estey E, Andreeff M, Trujillo J, Cork MA, 
Smith TL, Benedict WF, and Deisseroth A: Clinical implications of altered retinoblastoma protein expression in newly diagnosed 
and relapsed acute myelogenous leukemia. Cancer Res 52:4587-4590, 1992. 
21. Zhang W, Hu G, Estey E, Hester J, and Deisseroth A: Altered conformation of the p53 protein in myeloid leukemia cells and 
mitogen-stimulated normal blood Cells. Oncogene 7:1645-1647, 1992. 
22. Estey E, Thall PF, Kantaijian H, O’Brien S, Koller CA, Beran M, Gutterman J, Deisseroth A, and Keating M; Treatment of 
newly diagnosed acute myelogenous leukemia with granulocyte-macrophage colony-stimulating factor (GM-CSF) before and during 
continuous-infusion high-dose ara-C + Daunorubicin: Comparison to patients treated without GM-CSF. Blood 79:2246-2255, 1992. 
23. Seong DC, Gottlieb K, Suh S-P, Sims S, Talpaz M, Kantaijian H, and Deisseroth A: Identification of a complex formed between 
nuclear proteins and the transcriptional enhancer of interferon-inducible genes that is present in the pieripheral blood myeloid cells 
of CML but not normal individuals. J Interferon Res 12:323-327, 1992. 
24 Gao P-<3, Sims SH, Chang DC, and Deisseroth AB: Interferon-gamma priming effects in the activation and deactivation of ISGF3 
m K562 cells. J Biol Chem 268:12380-12387, 1993. 
25. Zhang W, Funk WD, Wright WE, Shay JW, and Deisseroth AB: Novel DNA binding of p53 mutants and their role in 
transcriptional activation. Oncogene 8:2555-2559, 1993. 
26. Zhang W, Cork A, Trujillo J, Calvert L, Hu G, Andersson B, and Deisseroth AB: Mutations of the p53 gene are associated with 
genetic instability and immortalization in myelogenous leukemia. Cancer Res Therapy Control 3:139-144, 1993. 
27. del Giglio A, O’Brien S, Ford RJ Jr, Manning J, Saya H, Keating M, Johnston D, Chamone DF, and Deisseroth AB; Proliferating 
cell nuclear antigen (PCNA) expression in chronic lymphocytic leukemia. Leukemia and Lymphoma 10:265-271, 1993. 
28. Reading CL, Huh YO, Estey EH, Claxton DF, Sanchez G, Terstapp>en LWMM, O’Brien MC, Baron S, and Deisseroth AB: 
Expression of unusual immunophenotypie combinations in acute myelogenous leukemia. Blood 81:3083-3090, 1993. 
29. Komblau SM, Chen N, del Giglio A, O’Brien S, and Deisseroth AB: Retinoblastoma protein expression is frequently altered 
in chronic lymphocytic leukemia. Cancer Res 54:242-246, 1994. 
30. Cha Y and Deisseroth AB: Human interferon regulatory factor 2 gene: intron-exon organization and functional analysis of 5’ 
flanking region. J Biol Chem 269:5279-5287, 1994. 
31. Hanania EG and Deisseroth AB: Serial transplantation shows that early hematopoietic precursor cells are transduced by MDR-1 
retroviral vector in a mouse gene therapy model. In Press, Cancer Gene Therapy . 1994. 
32. Deisseroth AB, Zu Z, Claxton D, Hanania EG, Fu S, Ellerson D, Goldberg L, Thomas M, Janicek K, Anderson WF, Hester 
J, Korbling M, Durett A, Moen R, Berenson R, Heimfeld S, Brenner M, Hamer J, Calvert L, Tibbits P, Talpaz M, Kantaijian 
H, Champlin R, and Reading C: Genetic marking shows that Ph-t- cells present in autologous transplants of chronic myelogenous 
leukemia contnbute to relapse after autologous bone marrow in CML. In Press, Blood . 1994. 
[544] 
Recombinant DNA Research, Volume 19 
